schemaVersion:

1-Z: Filer Information

Issuer CIK
0001726711 
Issuer CCC
XXXXXXXX 
File Number
 
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? Radio button not checked Yes Radio button checked No
Successor File Number
 
Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
Is this an electronic copy of an official filing submitted in paper format? Checkbox not checked
Would you like a Return Copy? Checkbox not checked

Submission Contact Information

Name
 
Phone
 
E-Mail Address
 
Notify via Filing Website only? Checkbox not checked

1-Z: PRELIMINARY INFORMATION

Exact name of issuer as specified in the issuer's charter

ADiTx Therapeutics, Inc. 

Address of Principal Executive Offices
Address 1

11161 Anderson Street 

Address 2

Suite 105-10014 

City

Loma Linda 

State/Country

CALIFORNIA  

Mailing Zip/ Postal Code

92354 

Phone

909-488-0844 

Commission File Number(s)

024-10825 

1-Z: PART I Summary Information Regarding the Offering and Proceeds

Summary Information

Date of qualification of the offering statement

09-11-2018 

Date of commencement of the offering

09-11-2018 

Amount of securities qualified to be sold in the offering

1666666 

Amount of securities sold in the offering

0 

Price per security:

$ 6.0000 

The portion of aggregate sales attributable to securities sold on behalf of the issuer

$ 0.00 

The portion of aggregate sales attributable to securities sold on behalf of selling securityholders:

$ 0.00 

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider Underwriters - Fees
$  
Sales Commissions - Name of Service Provider Sales Commissions - Fee
$  
Finders' Fees - Name of Service Provider Finders' Fees - Fees
$  
Accounting or Audit - Name of Service Provider Accounting or Audit - Fees
$  
Legal - Name of Service Provider Legal - Fees
$  
Promoters - Name of Service Provider Promoters - Fees
$  
Blue Sky Compliance - Name of Service Provider Blue Sky Compliance - Fees
$  
CRD Number of any broker or dealer listed

 

Net proceeds to the issuer

$ 0.00 

Clarification of responses (if necessary):

1-Z: PART II Certification of Suspension of Duty to File Reports

Certification

Title of each class of securities covered by this Form

Common Stock, Warrants

Commission File Number(s)

024-10825 

Approximate number of holders of record as of the certification date

42 

1-Z: Signature

Signature

Pursuant to the requirements of Regulation A,

Cik

0001726711 

(Name of issuer as specified in charter)

ADiTx Therapeutics, Inc.

certifies that it meets all of the conditions for termination of Regulation A reporting specified in Rule 257(d) and that there are no classes of securities other than those that are the subject to this Form 1-Z regarding which the issuer has Regulation A reporting obligations.

(Name of issuer as specified in charter)

ADiTx Therapeutics, Inc.

Has caused this certification to be signed on its behalf by the undersigned duly authorized person.

By

/s/ Amro Albanna 

Date

04-29-2019 

Title

Chief Executive Officer

Instructions: This Part II of Form 1-Z is required by Rule 257(d) of Regulation A. An officer of the issuer or any other duly authorized person may sign, and must do so by typed signature. The name and title of the person signing the form must be typed or printed under the signature. The signatory to the filing must also manually sign a signature page or other document authenticating, acknowledging or otherwise adopting his or her signature that appears in the filing. Such document must be executed before or at the time the filing is made and must be retained by the issuer for a period of five years. Upon request, the issuer must furnish to the Commission or its staff a copy of any or all documents retained pursuant to this instruction.